Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.

Excluding these special items, adjusted loss per share was 72 cents compared with a loss of 85 cents per share in the ...

DoP rejects Aristo Pharma’s review application for its multivitamin tablets: Gireesh Babu, New Delhi Friday, November 8, 2024, 08:00 Hrs [IST] The Department of Pharmaceuticals ...

The drug candidate is administered orally in the form of a film-coated tablet ... in the UK and around the world. AstraZeneca submitted a compliant application for the clinical study to the ...

The towers and rotating blades of the wind turbines emit radar echoes and generate other forms of interference ... The ...

actual application of our TissueCypher test may not provide the aforementioned benefits to patients; and the risks set forth under the heading "Risk Factors" in our Annual Report on Form 10-K for the ...

In September 2024, the U.S Food and Drug Administration cleared Innate's investigational new drug (IND) application ... in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, ...

LONDON, Nov 6 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not know the reason ...

The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca ...

AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Tezspire has shown promising results in the Phase III WAYPOINT trial, ...